secwatch.observer — SEC 8-K summary
======================================

Issuer:     PHIBRO ANIMAL HEALTH CORP (PAHC)
CIK:        0001069899
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001104659-26-056316
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phibro Animal Health Q3 FY2026: Sales $383.5M (+10%), Adj. EBITDA $60.8M (+11%); Guidance raised
--------------------------------------------------------------------------------

- Q3 net sales $383.5M, +10% YoY; Animal Health segment +13% to $291.2M, driven by MFA portfolio, nutritional specialties, vaccines.
- Net income $24.0M, +15%; diluted EPS $0.59; adjusted diluted EPS $0.76, +19% YoY.
- Updated FY2026 guidance: net sales $1.46B-$1.50B (14% growth), adjusted EBITDA $247M-$255M (37% growth).
- Post-quarter: expanded revolver by $125M to $435M; announced Sustainable Solutions Platform with VERRATAIN; Brazil regulatory development on antimicrobials noted.
- Gross margin improved 270 bps to 32.8%; free cash flow $12.8M trailing twelve months; leverage 3.1x.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069899/000110465926056316/0001104659-26-056316-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069899/000110465926056316/pahc-20260506x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-056316

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer